MiMedx Group, Inc (NASDAQ:MDXG) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of MiMedx Group, Inc (NASDAQ:MDXG) have been given an average recommendation of “Moderate Buy” by the seven brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $8.5714.

Several equities research analysts have issued reports on the company. Seaport Research Partners cut MiMedx Group to a “neutral” rating in a research note on Monday, August 17th. Craig Hallum increased their price target on MiMedx Group from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Thursday, August 27th. Weiss Ratings raised MiMedx Group from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, August 27th. Raymond James Financial set a $8.00 price objective on shares of MiMedx Group in a report on Monday, August 17th. Finally, Wall Street Zen raised shares of MiMedx Group from a “sell” rating to a “hold” rating in a research report on Saturday, August 29th.

Institutional Investors Weigh In On MiMedx Group

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Engineers Gate Manager LP boosted its position in shares of MiMedx Group by 88.6% during the 2nd quarter. Engineers Gate Manager LP now owns 38,525 shares of the company’s stock worth $148,000 after purchasing an additional 18,103 shares during the period. Squarepoint Ops LLC raised its position in MiMedx Group by 73.7% in the second quarter. Squarepoint Ops LLC now owns 571,930 shares of the company’s stock valued at $2,202,000 after purchasing an additional 242,714 shares during the period. HB Wealth Management LLC purchased a new stake in MiMedx Group in the second quarter valued at approximately $51,000. Syon Capital LLC acquired a new position in MiMedx Group during the second quarter worth $45,000. Finally, Susquehanna International Group LLP lifted its stake in MiMedx Group by 26.2% during the second quarter. Susquehanna International Group LLP now owns 72,716 shares of the company’s stock worth $280,000 after purchasing an additional 15,101 shares in the last quarter. 79.15% of the stock is owned by hedge funds and other institutional investors.

MiMedx Group Price Performance

Shares of MDXG stock opened at $4.69 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.33 and a quick ratio of 4.79. The company has a market capitalization of $683.61 million, a PE ratio of 117.28 and a beta of 1.43. The firm’s 50-day moving average is $4.37 and its two-hundred day moving average is $4.03. MiMedx Group has a 12 month low of $3.03 and a 12 month high of $7.97.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). The business had revenue of $64.36 million during the quarter, compared to analysts’ expectations of $63.46 million. MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. Analysts predict that MiMedx Group will post -0.1 earnings per share for the current year.

MiMedx Group Company Profile

MiMedx Group, Inc is a biotechnology company that develops and markets regenerative biologic products derived from human placental tissue. Its products are designed to support the body’s natural healing processes and are used by healthcare professionals in wound care, surgical applications, and musculoskeletal treatment.

The company’s portfolio includes dehydrated human amnion/chorion membrane allografts, including EPIFIX, AMNIOFIX, and AMNIOCORD. These products are used in applications such as chronic wound management, tissue repair, and protection of soft tissue.